PACAP38 is a potent aggravator of migraine, a new study shows. This provides several new potential therapeutic targets -- most prominently a specific PACAP receptor PAC1.
Bert B. Vargas, MD
Intriguing research is helping to shape our understanding of the functional connectivity and brain structure of migraineurs.
Highlights of the first large study to describe the characteristics of post-traumatic headache and treatment response in children are summarized here.
A novel drug-device may not only be a promising non-oral triptan acute migraine treatment, but may be more efficacious than its oral counterpart.
Despite butterbur’s potential efficacy, doubts are increasing about its long-term safety given of the risk of liver damage and the lack of an actively regulated preparation.